Wandercraft
walks the machine

It began with a question a boy asked his father. Oscar Constanza, a teenager who used a wheelchair, looked at his dad - a robotics engineer - and said: why don't you make a robot that would allow us to walk? That question, and a founding team who refused to accept the wheelchair as the last word in mobility, became Wandercraft. Thirteen years later, the Paris company's exoskeletons are in more than 100 rehabilitation centers, and its technology has crossed into a market almost no one expected: industrial humanoid robots.

Wandercraft was founded in 2012 by engineers drawn largely from the École Polytechnique robotics community in Paris - among them Matthieu Masselin, now CEO; Nicolas Simon, now president; Alexandre Boulanger; and Jean-Louis Constanza, Oscar's father. Several founders had personal ties to degenerative mobility loss, including Charcot-Marie-Tooth disease, an inherited condition that erodes the ability to walk. That gave the company an unusual center of gravity: a hard engineering problem paired with a reason not to give up on it.

01 / What it doesThe problem of staying upright

Most exoskeletons keep a user standing by leaning on crutches. Wandercraft's central technical achievement is removing them. Its machines are self-balancing: onboard control software reads the body's motion and continuously adjusts to keep the wearer stable, hands-free. That single capability - staying upright while walking, without external support - is one of the hardest problems in legged robotics, and it is the thread that connects everything the company builds.

The payoff for a person is not abstract. Hands-free means a free hand to open a door, hold a cup, or reach for a shelf. For a clinic, it means a patient can train an upright, natural gait pattern rather than a shuffling, crutch-bound one. For Wandercraft, the same balance math that keeps a person steady turned out to keep a robot steady too.

02 / The productsThree machines, one platform

The company now ships and develops three distinct products, all built on the same self-balancing foundation.

03 / Who it servesFrom the clinic to the living room to the line

Wandercraft's customers fall into three groups. The first are rehabilitation hospitals, neurology and physical-therapy clinics, and VA medical centers that use Atalante X for gait therapy. The second - the market Eve is built for - are individuals living with spinal cord injury, stroke, or other conditions who want to stand and walk at home. The third, newest group is industrial: manufacturers, led by Renault Group, that want humanoids for physically punishing work.

To reach home users, Wandercraft named National Seating & Mobility its exclusive US distribution partner for Eve - a network of more than 180 locations for evaluation, fitting, and delivery - and is targeting Medicare-eligible reimbursement, the kind of coverage that decides whether a device reaches thousands or millions.

04 / What makes it differentOne balance engine, two industries

In medical exoskeletons, Wandercraft competes with names like Ekso Bionics, ReWalk/Lifeward, and Cyberdyne. In humanoids, the field is crowded with Figure AI, Agility Robotics, Apptronik, and Tesla's Optimus. What sets Wandercraft apart is the crossover: it did not start in humanoids and reach toward the body, nor start in medtech and stay there. It spent more than a decade solving dynamic balance on the human form, then discovered that expertise transferred directly to a walking industrial robot.

That crossover produced Calvin-40's headline feat - a working humanoid built in 40 days. The speed was not luck. It was the dividend of a mature robotics platform, combined with NVIDIA's Isaac stack: Calvin trains in the Omniverse Isaac Sim simulator, runs on Jetson edge computing, and draws on the Isaac GR00T N1 foundation model. Calvin is deliberately headless - engineered for factory work, not human resemblance.

05 / The businessTwo markets, one bet

Wandercraft runs a dual-market hardware-and-services model. On the health side, it sells and supports Atalante X to clinics and is building consumer distribution for Eve. On the industrial side, it develops and deploys Calvin under a commercial partnership with Renault, which is both an investor and a customer - a combination that gives a hardware startup rare validation. Renault's roadmap calls for around ten robots in place by the end of 2026 and 350 across French and Spanish factories by the end of 2027.

The company reports roughly 150 employees and an estimated annual revenue in the mid-eight figures - a figure that reflects a business still early in commercializing two of its three products.